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Abstract
Background: Understanding the genetic modifiers of neurodegenerative diseases can provide insight into the
mechanisms underlying these disorders. Here, we examine the relationship between the motor neuron disease
spinal muscular atrophy (SMA), which is caused by reduced levels of the survival of motor neuron (SMN) protein,
and the actin-bundling protein Plastin 3 (PLS3). Increased PLS3 levels suppress symptoms in a subset of SMA
patients and ameliorate defects in SMA disease models, but the functional connection between PLS3 and SMN is
poorly understood.
Results: We provide immunohistochemical and biochemical evidence for large protein complexes localized in
vertebrate motor neuron processes that contain PLS3, SMN, and members of the hnRNP F/H family of proteins.
Using a Caenorhabditis elegans (C. elegans) SMA model, we determine that overexpression of PLS3 or loss of the C.
elegans hnRNP F/H ortholog SYM-2 enhances endocytic function and ameliorates neuromuscular defects caused by
decreased SMN-1 levels. Furthermore, either increasing PLS3 or decreasing SYM-2 levels suppresses defects in a C.
elegans ALS model.
Conclusions: We propose that hnRNP F/H act in the same protein complex as PLS3 and SMN and that the
function of this complex is critical for endocytic pathways, suggesting that hnRNP F/H proteins could be potential
targets for therapy development.
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Background
Neurodegenerative diseases are widespread and usu-
ally incurable. The identity of disease-causing genes is
frequently known, but the mechanisms and pathways
underlying disease onset, progression, and pathology
remain elusive. The motor neuron disease spinal mus-
cular atrophy (SMA) is caused by reduced levels of
the survival of motor neuron (SMN) protein.
Decreased SMN in SMA patients impacts the func-
tion of alpha motor neurons, resulting in their dys-
function, degeneration, and consequent muscular
atrophy. SMN is required for the biogenesis of small
nuclear ribonucleoproteins (snRNPs), which are crit-
ical for pre-mRNA splicing [1–3]. SMN is also found
in stress granules and other RNP granules in neuronal
processes [4–7], and other studies have identified
roles for SMN in microRNA biogenesis and endocytic
pathways [8–11]. Determining which of these various
granules and RNP-related pathways are most pertin-
ent to SMA pathogenesis is critical. To dissect this,
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we turn to genetic modifiers of SMA. Understanding
why these modifiers suppress SMA-associated defects
should reveal pathways critical for SMA pathogenesis.
Plastin 3 (PLS3) was identified as a genetic modifier in
type III SMA discordant families, where six asymptom-
atic individuals had elevated PLS3 levels [12]. PLS3 is a
calcium-dependent actin-bundling protein involved in
many processes, including cell migration, adhesion,
vesicle trafficking, and endocytosis [13, 14]. PLS3 over-
expression ameliorates defects in many mouse, zebrafish,
and tissue culture models of SMA [9, 15–18]. Because
overexpression of PLS3 does not increase SMN protein
levels or overtly change SMN localization, PLS3 likely
acts with or downstream of SMN to suppress defects in
SMA. There is no evidence that PLS3 and SMN proteins
directly interact, but both pull down together in a large
protein complex that also contains actin [12].
Previous work has demonstrated that decreased SMN
function causes endocytic pathway defects. Endocytic
defects are seen in C. elegans, mouse, and tissue culture
models of SMA [8–10, 19]. These defects are also found
in less severe models of SMA where SMN decreases are
not sufficient to cause motor neuron loss. PLS3 overex-
pression suppresses these endocytic pathway defects in
tissue culture cells and in an intermediate SMA mouse
model, which was generated using antisense oligonucleo-
tides (ASO) targeting SMN [9]. Moreover, two novel
PLS3 interacting proteins have been identified and
shown to be involved in the endocytosis process: overex-
pression of coronin 1C (CORO1C)—an F-actin binding
and bundling protein—and downregulation of
calcineurin-like EF-hand protein 1 (CHP1)—a calcium
sensor and inhibitor of calcineurin that collectively de-
phosphorylates proteins involved in endocytosis—both
rescue impaired endocytosis in SMA [9, 19].
Another genetic modifier, independently isolated in
SMA patient families, also impacts endocytic pathway
function. Neurocalcin delta (NCALD) encodes a small
Ca2+ binding protein that acts as a neuronal calcium
sensor. Loss of NCALD suppresses defects in mouse, C.
elegans, and zebrafish SMA models, including the previ-
ously described endocytic defects [10]. Combined, the
analysis of these four human genetic modifiers suggests
that endocytic pathway defects in SMA may be critical
contributors to SMA pathogenesis. We hypothesize that
the protein complex containing SMN, PLS3, and actin
may be critical for endocytic pathway function when
SMN levels drop, but our poor understanding of this
protein complex hinders progress.
Furthermore, understanding the interaction between
PLS3 and SMN could provide insight into other neuro-
degenerative diseases including ataxia and amyotrophic
lateral sclerosis (ALS). Indeed, recently we reported that
PLS3 overexpression is beneficial in CHP1-related ataxia
in mice that carry biallelic Chp1 mutation [20]. Key pro-
teins have been identified linking ALS and SMA. Several
of these proteins function in splicing, mRNP transport,
and other processes that overlap with the function of
SMN [21–24]. SMN is also known to have a well-
established interaction with a group of proteins known
as GEMINs, and loss of GEMINs is a cellular hallmark
of SMA [25]. Interestingly, studies have also shown that
Gemin levels are affected in various models of ALS in-
cluding SOD1 models [26–28]. These studies along with
a recently published work that undertook a gene ontol-
ogy enrichment analysis of published ALS modifier
genes found an overlap in shared pathways that may
underlie ALS and are also involved in SMA [29]. With
evidence that similar pathways and genes are affected
across multiple neurodegenerative diseases, it is crucial
that one takes into consideration the possibility that a
genetic modifier of SMA might also modify ALS.
Therefore, in this study, we focus on understanding
the genetic interaction between PLS3 and SMN and test-
ing if similar genetic interactions occur in a C. elegans
model of ALS through behavioral analysis. We demon-
strate that increased PLS3 expression suppresses loco-
motion defects in an established C. elegans model of
SMA. Through a combination of approaches in C. ele-
gans and vertebrate systems, we identify novel proteins
in the PLS3/SMN complex. Using genetic and behavioral
tools available in C. elegans, we demonstrate that per-
turbing the function of these novel proteins modifies de-
fects in SMA models and we identify the hnRNP F/H
ortholog, sym-2, as a novel genetic suppressor of smn-1
loss of function defects. We find that PLS3, SMN, and
hnRNP F/H are in a large protein complex in vertebrate
motor neuron processes. Furthermore, we find that simi-
lar to PLS3 overexpression, decreasing hnRNP F/H sup-
presses defects in endocytic pathways caused by reduced
SMN levels. Finally, increased expression of PLS3 or de-
creased expression of hnRNP F/H orthologs suppresses
locomotion defects in a C. elegans ALS model [30].
Taken together, these results demonstrate that PLS3,
SMN, and hnRNP F/H are functional members of a pro-
tein complex that is pertinent to SMA and that the
mechanism underlying PLS3 or hnRNP F/H suppression
is likely altering endocytic pathway activity. In addition,
the suppression of ALS behavioral defects in a C. elegans
model by increasing PLS3 or decreasing SYM-2 expres-
sion shows that conserved pathways are affected across
motor neuron diseases.
Results
SMN function is essential for proper recovery after
exhaustion
The C. elegans genome contains a single ortholog of
SMN, encoded by the smn-1 gene. The severe loss of
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function allele, smn-1(ok355), has impaired neuromuscu-
lar function, and animals usually die during larval develop-
ment, despite the fact that premature motor neuron death
is not observed [31, 32]. A less severe allele, smn-1(cb131),
is viable, fertile, and has only subtle defects. smn-1(cb131)
is a D27N amino acid substitution, analogous to a D44V
allele found in a type III SMA patient [33, 34]. The loco-
motion of smn-1(cb131) animals is normal on solid sur-
faces [35], and we observed no locomotion defects in
animals swimming in liquid (assessed as body bends per
minute in developmental stage matched animals, Fig. 1b
pre-exposure time point, p = 0.746). However, smn-
1(cb131) animals are resistant to immobilization by pyri-
dostigmine bromide, an acetylcholinesterase inhibitor,
suggesting latent defects in cholinergic neuromuscular
junction (NMJ) synapse function [35].
Liewald and colleagues showed that channelrhodopsin
(ChR2) stimulation of C. elegans cholinergic motor neu-
rons depletes synaptic vesicle pools and results in transi-
ently decreased locomotion post-stimulation [36, 37].
Using this paradigm (Fig. 1a and detailed description in
the “Methods” section), we challenged NMJ function in
smn-1(cb131) animals. As a result, cholinergic motor
neuron stimulation in smn-1(cb131) animals revealed a
locomotion defect during recovery after exhaustion, only
in the presence of retinal. Before the blue light activation
of cholinergic ChR2, locomotion rates of smn-1(cb131)
and control animals were indistinguishable. After ChR2
activation for 20 s, locomotion rates decreased in both
smn-1(cb131) and control animals. However, the post-
exhaustion decrease was more profound in smn-
1(cb131) animals (locomotion rates were 58% of con-
trols, Fig. 1b, p = 0.001). smn-1(cb131) locomotion was
restored to control levels 20 min after stimulation
(Fig. 1b, p = 0.869), arguing against neuron or synapse
damage caused by ChR2 activation and more likely a de-
layed recovery after exhaustion in these animals. Thus,
we conclude that a latent defect in recovery after ex-
haustion is revealed in smn-1(cb131) by ChR2 stimula-
tion of cholinergic neuron activity.
To test if smn-1(cb131) defects are caused by dimin-
ished SMN-1 levels, we undertook transgenic rescue
studies. A single copy of the C. elegans smn-1 gene, in-
cluding promoter, exons, introns, and 3′ untranslated
sequences, was inserted into another chromosome by
site-directed homologous recombination, creating
rtSi10[smn-1p::smn-1] [8]. This transgene restored nor-
mal recovery rates after exhaustion in smn-1(cb131);
ChR2 animals (smn-1(cb131);rtSi10 versus smn-1(cb131),
Fig. 1c, p = 0.043). Therefore, diminished levels of SMN-
1 impair recovery after exhaustion in smn-1(cb131) ani-
mals. Next, we used this ChR2 exhaustion assay to assess
the impact of PLS3, a previously identified genetic modi-
fier [12, 16].
Increased expression of plastin in neurons suppresses
smn-1(cb131) locomotion defects
PLS3 is a protective modifier of SMA; increased PLS3
levels suppress defects in humans and SMA models
in zebrafish, flies, and mice [9, 12, 16, 38–40]. We
determined whether increasing PLS3 levels would
ameliorate various functional defects in C. elegans
SMA models.
First, we assessed locomotion after ChR2 exhaustion
to determine if the introduction of human PLS3 could
restore locomotion when SMN-1 function is de-
creased. We introduced two transgenes; a single-copy
transgene (rtSi27[dpy-30p::PLS3]) or a multi-copy
transgene (rtIs59 [dpy-30p::PLS3]) was crossed onto
the smn-1(cb131);ChR2 background. In both cases,
human PLS3 was expressed ubiquitously in somatic
tissues using the dpy-30 promoter [41]. We found
that PLS3 overexpression restored post-exhaustion
locomotion rates to normal levels in smn-1(cb131) an-
imals (after cholinergic ChR2 neuron stimulation,
Fig. 2a, p = 0.002 and 0.003). Therefore, we conclude
that expression of human PLS3 ameliorates the func-
tional defects caused by decreased SMN-1 in this ex-
haustion paradigm.
To test for cross-species conservation of plastin
function, we also examined the impact of overex-
pressing the C. elegans PLS3 ortholog, plst-1. Loss of
plst-1 exacerbates smn-1 neuromuscular defects in
other paradigms [39]. We assessed locomotion in
smn-1 mutant animals that ubiquitously express C.
elegans plst-1 mRNA at increased levels (rtEx850
[dpy-30p::plst-1]). The multi-copy plst-1 transgene re-
stored normal locomotion rates after exhaustion in
smn-1(cb131);ChR2 animals (Fig. 2a, p = 0.006). Com-
bined with previous loss of function studies [39], our
results are consistent with the hypothesis that Plastin
3 and its C. elegans ortholog are cross-species modi-
fiers of locomotion defects in SMA models.
SMN is broadly expressed, but its function is required
in motor neurons for normal NMJ activity, based on
work in mammalian [42] and C. elegans SMA models
[31]. Plastin 3 is also broadly expressed in neuronal and
non-neuronal tissues [43]. To determine where PLS3
function is required in C. elegans SMA models, we
expressed PLS3 in either body wall muscle or neurons of
smn-1(cb131) animals. Expression of human PLS3 in
neurons (rtEx852[unc-119p::PLS3]), but not in muscles
(rtEx851[myo-3p::PLS3]), restored normal recovery of
locomotion rates after exhaustion in smn-1(cb131);ChR2
animals (Fig. 2b, p = 0.05 and p = 0.237, versus no PLS3,
respectively). This is consistent with studies of PLS3 and
SMN in vertebrate models, where increasing PLS3 in
neurons was also sufficient to ameliorate defects when
SMN levels decreased [16].
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Fig. 1 (See legend on next page.)
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Finally, we examined the impact of increased PLS3 activ-
ity in otherwise normal animals. A single-copy insertion of
the ubiquitously expression dpy-30p::PLS3 transgene had
no impact on basal locomotion; activity in liquid was indis-
tinguishable from control animals. However, further in-
crease in PLS3 dosage did alter locomotion. A transgene
generated at higher concentrations of dpy-30p::PLS3, rtIs59,
increased basal locomotion rates by 38% (Fig. 2c, p = 0.003).
However, it is unclear whether the increased locomotion of
these high copy PLS3 overexpression animals is pertinent
to the impact of PLS3 in SMA models. We cannot rule out
that a high dosage of PLS3 is detrimental because it has
been shown that high levels of the analogous actin-
bundling protein Sac6 cause lethality in yeast [44]. There-
fore, we avoided use of this high copy PLS3 transgene in
the rest of this study, unless explicitly noted.
(See figure on previous page.)
Fig. 1 Rescue of smn-1(cb131) exhaustion defects by reintroduction of smn-1(+). a Schematic representation of experimental design.
Channelrhodopsin is expressed in cholinergic motor neurons. After overnight retinal feeding, animals are exposed to blue light stimuli for 20 s in
liquid and body bends per minute are recorded over time. A body bend is defined as a muscle contraction resulting in a dorsal to ventral
movement across the midline of the animal. b Before blue light stimulation, animals have almost identical locomotion (data points shown in
gray). After 20 s blue light stimulation of channelrhodopsin (ChR2) in cholinergic neurons, smn-1(cb131) partial loss of function animals had
decreased locomotion rates when fed retinal and had delayed recovery to original activity. Animals not fed retinal are shown immediately
following blue light exposure in a hashed box. Locomotion reported as body bends per minute in liquid. c Introduction of an smn-1 genomic
transgene restored normal locomotion rates immediately following blue light illumination. [smn-1(+)] is rtSi10, a homozygous single-copy
insertion on chromosome IV (see Additional file 1: Table for details); ANOVA F(3.32, 12.5) = 7.27, p < 0.05. All animals carry oxIs364[unc-17p::ChR2]
and exhibit no change in locomotion without exogenous retinal feeding (data not shown). The drop in body bends per minute from panel b to
c is due to methodology. Panel b is counted manually by eye whereas panel c and future locomotion rates are calculated using the NABAS
program described in the “Methods” section. For all locomotion assays, n ≥ 30 animals were used per determination and combined from 3
independent and blinded trials. Student’s t test: *p < 0.05, **p < 0.01. SEM indicated
Fig. 2 Neuronal expression of human PLS3 restores normal locomotion in smn-1(cb131) animals. a Locomotion rates of smn-1(cb131) animals
decreased after a 20-s blue light stimulation of ChR2 in cholinergic neurons, in the presence of retinal. Introduction of somatic expression of
human Plastin 3 (PLS3) restored normal locomotion rates immediately post-exhaustion. Two different PLS3 transgenes were used. Low copy is a
homozygous single-copy insertion of [dpy-30p::PLS3], rtSi27 on chromosome II; high copy is an integrated multi-copy transgene incorporating the
same transgene as low copy, rtIs59. Ubiquitous overexpression of the C. elegans ortholog of PLS3 (plst-1) was equally effective rtEx850. ANOVA
F(2.9, 13.5) = 3.33, p < 0.05. b Neuronal expression of PLS3 rtEx852 [unc-119p::PLS3] rescued the post-exhaustion locomotion defects of smn-
1(cb131) animals; expression in muscles rtEx851 [myo-3p::PLS3] did not. ANOVA F(1.56, 10.28) = 4.25, p < 0.05. c Overexpression of human PLS3 at
high copy levels using rtIs59 increased basal locomotion rates in a wild-type background compared to controls. d smn-1(cb131) mutant animals
were resistant to the cholinesterase inhibitor aldicarb, based on slower time to paralysis. Introduction of ubiquitously expressed human PLS3
restored sensitivity to normal levels. Note that C. elegans plst-1 was intact in all genotypes reported here and control animals contained the
transgene rtSi28 [dpy-30p::empty] to account for insertion site and/or multi-copy promoter effects. In all assays, n ≥ 30 animals per determination,
combined from 3 independent trials. Scorers were blinded to the genotypes of animals during the collection and analysis of data for the
locomotion and aldicarb sensitivity assays. Student’s t test, Mann-Whitney U test (a–c), or log rank test (d): *p < 0.05, **p < 0.01. SEM indicated
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Increasing plastin levels ameliorates NMJ and pharyngeal
pumping defects caused by decreased smn-1 function
smn-1(cb131) animals are resistant to paralysis by the
acetylcholinesterase inhibitor, pyridostigmine bromide,
suggesting reduced cholinergic NMJ function [35].
We found that diminished SMN-1 function also re-
sulted in decreased sensitivity to aldicarb, another
acetylcholinesterase inhibitor. Prolonged exposure to
aldicarb gradually induces paralysis, due to acetylcho-
line accumulation in the synaptic cleft. smn-1(cb131)
animals paralyze more slowly on aldicarb than control
animals (Fig. 2d, log rank p = 0.009). Introduction of
the human PLS3 multi-copy transgene into smn-
1(cb131) animals restored normal aldicarb sensitivity
(Fig. 2d, p = 0.009 versus transgenic control lacking
PLS3). These results indicate that ubiquitous PLS3 ex-
pression improves cholinergic NMJ function when
SMN-1 is impaired.
Various studies show that the effects of PLS3 may
depend on the levels of SMN present. In models
where SMN levels are substantially decreased, in-
creased PLS3 insufficiently suppresses neuromuscular
defects [15, 16]. However, to test if the beneficial im-
pact of PLS3 is not limited to smn-1(cb131) animals,
we also tested smn-1(ok355) severe loss of function
animals, which contain even lower levels of SMN-1
activity compared to smn-1(cb131). smn-1(ok355) ani-
mals have decreased pharyngeal pumping rates, a be-
havior frequently used to assess neuromuscular
function. C. elegans feed on bacteria using a dedicated
set of muscles and neurons in the pharynx.
Pharyngeal pumping rates average roughly 250 pumps
per minute in the presence of food; late larval stage
smn-1(ok355) animals have dramatically reduced
pharyngeal pumping rates [31, 39]. In control animals
with a wild-type smn-1 gene, ubiquitous expression of
human PLS3 in C. elegans slightly decreased pumping
rates (single-copy transgene, rtSi27, − 11% versus wild
type, Additional file 1: Fig. S1, p = 0.002). However,
the introduction of the single-copy PLS3 transgene
into smn-1(ok355) animals increased pharyngeal
pumping rates by 50% (Additional file 1: Fig. S1, ver-
sus ok355 p = 0.011). Although pumping rates were
not restored to wild-type levels, we conclude that in
severe loss of function smn-1 animals, increased PLS3
partially ameliorates neuromuscular defects. Using
two different alleles and testing multiple defects, an
overexpression of PLS3 proves beneficial when SMN
levels are decreased in C. elegans. This concurs with
the partial amelioration observed in particular type
IIIb SMA patients that carry two SMN2 copies and
have elevated levels of PLS3 [12]. Taken together, our
results demonstrate that plastin is a conserved genetic
modifier of neuromuscular function.
Identification of sym-2 as a genetic modifier of both PLS3
and smn-1
PLS3, SMN, and actin can be co-precipitated from
HEK293T cells and murine spinal cord, but SMN
does not directly interact with PLS3. The identity of
other proteins in this complex is unknown [12]. De-
lineating other proteins in the PLS3/SMN complex
would lead to a better understanding of SMA and
the protective mechanism engaged by increased PLS3
levels. To identify these other proteins, we under-
took a small, targeted screen starting with results
from a previous large-scale proteomic study under-
taken in Drosophila S2 cells [40]. From those results,
we assembled a list of proteins that pulled down ei-
ther with Drosophila SMN or with Drosophila Fim-
brin, the PLS3 ortholog. We prioritized proteins
found in both lists, based on frequency of pull-down;
protein similarity between D. melanogaster, H. sapi-
ens, and C. elegans; and the availability of C. elegans
loss of function (lf) alleles. From this, eleven C. ele-
gans candidate genes were targeted for functional
analysis (Fig. 3a). We hypothesized that proteins in
the same protein complex as SMN and PLS3 might
show functional interactions, and we interrogated
these putative interactions by testing if C. elegans
candidate gene loss of function suppressed PLS3-
and SMN-associated defects. High copy PLS3 expres-
sion results in aberrantly high locomotion levels in
liquid (Figs. 2c and 3b). We determined if candidate
gene loss of function alleles could suppress locomo-
tion changes caused by increased PLS3.We also de-
termined if candidate gene loss of function could
suppress the defect in smn-1(cb131) recovery from
ChR2-induced exhaustion. Only sym-2 loss of func-
tion ameliorated defects in these assays (Fig. 3b, p =
0.007, and c, p = 0.006). RNAi knockdown of sym-2
also suppressed smn-1(cb131) ChR2-induced exhaus-
tion recovery defects (Additional file 1: Fig. S2, p =
0.02, smn-1(cb131) control versus knockdown of
sym-2), but knockdown of genes encoding two re-
lated C. elegans proteins had no impact (hrpf-1 and
hrpf-2, Additional file 1: Fig. S2). Glorund was iden-
tified from the proteomic Drosophila screen, and
BLAST results list the orthologs sym-2, hrpf-1, and
hrpf-2 in C. elegans. BLAST results also show the
human orthologs to glorund as hNRNP F, H1, H2,
GRSF1, and ESRP 1 and 2. Based on predicted func-
tional domains and expression patterns, the human
proteins most closely related to glorund and SYM-2
are hnRNP F, hnRNP H1, and hnRNP H2 [46].
Members of this heterogeneous nuclear ribonucleo-
protein family have roles in pre-mRNA processing
[42, 47, 48]. Given the results above, we chose to
focus on sym-2 for the remainder of this study.
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sym-2(mn617) is a Y163N missense allele that likely
decreases SYM-2 function [46]. As described above,
introduction of sym-2(mn617) into the PLS3 overex-
pression background returned locomotion rates to
normal (Fig. 3b, p = 0.007). And, introduction of sym-
2(mn617) ameliorated smn-1(cb131) post-exhaustion
locomotion defects in double mutant animals (Fig. 3c
smn-1(cb131); sym-2(mn617) versus smn-1(cb131), p =
0.006). Taken together, these results demonstrate that
decreased sym-2 function suppresses defects caused
by decreased smn-1 activity or increased PLS3
function.
Fig. 3 Identification of sym-2 as a suppressor of PLS3oe and smn-1 locomotion defects. a To find proteins in a putative SMN/PLS3 complex, we
focused on candidates that independently pulled down in previous work [45] with both Drosophila Fimbrin and Drosophila Smn (left and right
circles of Venn diagram, details in the “Methods” section). Candidates that had a corresponding C. elegans loss of function allele available in 2011
are listed and were examined. Only sym-2 loss of function suppressed PLS3oe and smn-1 defects in all three assays (right) used to screen these
candidates. b Overexpression of human PLS3 increased basal locomotion rates compared to control animals. PLS3 was overexpressed from rtIs59,
an integrated multi-copy transgene ubiquitously driving expression using the dpy-30 promoter. Decreased function of the C. elegans hnRNP F/H
ortholog, sym-2, did not change locomotion rates in a wild-type background, but sym-2 perturbation suppressed increased locomotion in PLS3oe
animals. ANOVA F(7962, 663) = 175.96, p < 0.05. c sym-2 perturbation suppressed locomotion defects in smn-1(cb131) animals immediately
following ChR2 exhaustion. All animals in c carried oxIs364[unc-17p::ChR2]; ANOVA F(0.84, 0.55) = 17.51, p < 0.05. In all assays, n ≥ 30 animals per
determination were used, combined from 3 independent trials. Scorers were blinded to the genotype of animals during the collection of data
and data analysis. Student’s t test: **p < 0.01. SEM indicated
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PLS3 colocalizes with SMN and SYM-2 orthologs in
vertebrate neurons
SMN-1, PLS3, and SYM-2 may act in a common func-
tional pathway, but C. elegans genetic studies cannot de-
termine if these proteins act in a conserved protein
complex in mammalian neurons. Previously, SMN pro-
tein was found in RNP granules with various hnRNPs in
neuronal processes, but not with hnRNP F/H orthologs
[48–50]. While the majority of studies focus on the nu-
clear role in splicing of hnRNP F/H, one cannot exclude
a possible role outside the nucleus [51, 52]. Therefore, a
series of immunohistochemical assays were done to look
for an association of hnRNP F/H with PLS3 and SMN
that might be pertinent in cells and occur outside the
nucleus.
First, we examined localization of PLS3, SMN, hnRNP
F, and hnRNP H1/2 in murine fibroblasts. Primary
cultures were generated from mice overexpressing a V5-
tagged PLS3 [16]. As expected, all four proteins were de-
tected in fibroblast nuclei using immunohistochemistry.
Interestingly, all four proteins are also present within
cytoplasmic filopodia, suggesting they function in the
same cellular compartment (Fig. 4a–d).
Next, we examined localization of hnRNP F, hnRNP
H1/2, PLS3, and SMN in the processes of cultured
mouse motor neurons. Embryonic stem cells were used
to generate neuronal cultures from mice expressing
motor neuron GFP (under the control of the Hb9 pro-
moter). After 13 days of growth in culture, endogenous
SMN, PLS3, hnRNP F, and hnRNP H1/2 proteins were
detected within neuronal processes using immunohisto-
chemistry. Each protein was distributed within motor
neuron processes. To quantitatively assess protein
localization within these structures, we used semi-
automated image analysis software (Columbus, Perkin
Elmer). By defining protein presence based on size, this
analysis showed that SMN independently localized to
the same region with all three proteins of interest in
these structures (Fig. 4e–g), allowing us to conclude that
hnRNP F and H1/2 are found in fibroblasts and in neur-
onal processes of motor neurons and that these proteins
frequently localize to the same region with SMN. Col-
lectively, these cellular data suggest that an association
may happen between SMN, PLS3, hnRNP F, and H1/2
in vivo.
SMN, PLS3, and SYM-2 orthologs co-exist in vertebrate
protein complexes
The localization analysis suggests that these proteins
might be found in a similar cellular compartment and
therefore could be in a complex together, a question we
addressed using co-immunoprecipitation studies.
HEK293T cells were transfected with tagged versions of
all four proteins. Immunoprecipitation of GFP-tagged
hnRNP F or hnRNP H1/2 revealed that these proteins
are associated with both SMN and PLS3 (Fig. 5a). The
interaction was not RNA-dependent, as associations
were maintained after RNase treatment (Additional file
1: Fig. S3). These results are consistent with the
localization analysis that show an interaction between
the proteins.
Co-immunoprecipitation from mouse brain lysates
confirmed an endogenous interaction between SMN and
PLS3, hnRNP F, or hnRNP H1/2 (Fig. 5b bracket) in
neuronal tissues. Reciprocally, endogenous PLS3 co-
immunoprecipitated with SMN, hnRNP F, and hnRNP
H1/2 (Fig. 5c). We conclude that SMN and PLS3 are in
protein complexes that also contain hnRNP F and/or
hnRNP H1/2 in the mouse brain. However, from this
evidence alone, one cannot conclude that hnRNP F or
hnRNP H1/2 are in a complex simultaneously contain-
ing both SMN and PLS3.
To test if these proteins are found in a complex
together, we undertook size fractionation of whole cell
lysates using FPLC columns and HEK293T cells express-
ing tagged versions of PLS3 and hnRNP F. In complexes
of less than 669 kDa and greater than 158 kDa, four pro-
teins—PLS3, SMN, actin, and hnRNP F—were found
(Fig. 5d). And, in the smaller complexes within this
range, hnRNP H1/2 also were found. Note that most of
the PLS3, actin, and hnRNP F/H1/2 proteins are found
in even smaller complexes, consistent with previously
described interactions of these proteins. Taken together,
size fractionation, co-immunoprecipitation, and
localization results suggest that a rare previously uniden-
tified complex may exist that contains actin, SMN, and
PLS3 as well as hnRNP F and/or hnRNP H1/2.
SYM-2 loss rescues smn-1 endocytosis defects
Fluid-phase endocytosis is perturbed in C. elegans with
decreased smn-1 function [8]. For mechanistic insight in
how sym-2 loss suppresses smn-1 defects, we used a
classical C. elegans assay which assesses endocytosis in
coelomocyte cells. Six coelomocyte cells are found in the
body cavity (pseudocoelom) of adult C. elegans. These
cells play a critical role in the active removal of proteins
by endocytosis [53, 54]. When muscle cells in transgenic
animals secrete soluble GFP into the pseudocoelom,
GFP is taken up by coelomocytes through fluid-phase
endocytosis and is sent for degradation. This assay has
been used extensively to characterize endocytic pathways
[55]. RNAi knockdown of smn-1 in coelomocytes im-
pairs GFP uptake and GFP clearance from the body cav-
ity, consistent with endocytic pathway defects [8]. We
found that either PLS3 overexpression or coelomocyte-
specific RNAi knockdown of sym-2 ameliorated endocy-
tic defects in smn-1(RNAi) animals. Overexpression of
PLS3 reduced the number of animals with GFP
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Fig. 4 (See legend on next page.)
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accumulation in the pseudocoelom (Fig. 6, p = 0.039),
consistent with the previously demonstrated role of
PLS3 in endocytic pathways [9]. Moreover, RNAi knock-
down of sym-2 dramatically improved GFP clearance
from the pseudocoelom of smn-1(RNAi) mutant animals
(Fig. 6, p = 0.1 × 10−5). These results demonstrate that
the endocytic pathway defects observed when smn-1
levels drop are counteracted by knockdown of sym-2 in
a cell autonomous manner. Combined with previous
work, these results suggest that SMN, PLS3, and hnRNP
(See figure on previous page.)
Fig. 4 hnRNPF and hnRNPH1/2 localize with SMN and PLS3 in fibroblasts and motor neuron processes. Murine embryonic fibroblasts’ (MEFs) cell
cultures were derived from Smn +/−; PLS3V5 tg/tg embryos and stained with V5 for PLS3 transgene; hnRNP-H1/2, hnRNP-F, and F-actin with
phalloidin. a PLS3V5 localized to the same region as hnRNP F. b hnRNP F similarly localized with SMN. c hnRNP H1/2 localized to the same
region with tagged PLS3. d hnRNP H1/2 localized to the same region with SMN. e SMN localized with PLS3 also in mouse spinal motor neurons
processes in primary culture. Motor neurons were derived from GFP-Hb9-expressing embryos, which labels motor neurons. Endogenous protein
was detected using immunohistochemistry. Quantitative analysis of cellular localization using confocal images of processes reports the
percentage of localization for SMN fluorescence within processes. Protein fluorescence criterion was manually set using controls within the
COLOMBUS software (Perkin Elmer), see the “Methods” section for details. f Localization of SMN with hnRNP F was seen using the same methods
as described in e. g Localization of SMN with hnRNP H1/2 was seen using the same methods as described in e. Protein localization assays were
done as three independent trials where each sample in each trial was a merge of images from multiple wells on a 96-well plate. Images were
taken using an automated program, and then, slices were chosen incorporating planes with the nuclei
Fig. 5 SMN, PLS3, hnRNP F, and hnRNP H1/2 associate in a large complex. a SMN and PLS3 independently associated with hnRNP H1/2 based on
co-immunoprecipitation from HEK293T cells transfected with tagged proteins. b Endogenous PLS3, hnRNP F, and hnRNP H 1/2 associated with
SMN in mouse brain extracts, based on immunoprecipitation with antisera against endogenous SMN protein. Arrowheads indicate the band of
interest in blots with multiple bands. Heavy and light chain bands are labeled when present. c Endogenous SMN, hnRNP F, and hnRNP H1/2
associated with endogenous PLS3 using the same approach outlined in b. Arrowheads indicate the band of interest in blots with multiple bands.
Heavy and light chain bands are labeled when present. IP on endogenous mouse brain extract was done from 3 independent brain extractions
and preparations. d Size fractionation studies of whole cell lysates from HEK293T cells showed that actin, SMN, PLS3, and hnRNP F and/or H1/2
proteins co-fractionate in complexes of the indicated size (bracket), although the bulk of hnRNP F/H1/2 protein is in other smaller complexes.
HEK293T cells were transfected with PLS3-Flag, and hnRNP F-GFP, endogenous hnRNP H1/2, actin, and SMN were detected using antisera
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F/H act in a protein complex, pertinent to SMA, whose
function is required for normal function of endocytic
pathways.
PLS3 expression suppresses defects in a C. elegans ALS
model
Increasing PLS3 levels accelerates neurite outgrowth in
vertebrate motor neurons, regardless of SMN status,
suggesting that increased PLS3 might impact general
function and survival of motor neurons [12]. With the
notion that common mechanisms may underlie neuro-
degenerative diseases, increased PLS3 expression may
modify defects associated with other neurodegenerative
diseases besides SMA [16, 20, 56]. Based on this hypoth-
esis, we determined if increasing PLS3 levels would
modify defects in an established C. elegans model of
ALS [30].
In the previously characterized C. elegans ALS model,
wild-type human SOD1 (SOD1-WT) or mutant human
SOD1 carrying the patient amino acid change G85R
(SOD1-G85R) are expressed at high levels using a pan-
neuronal C. elegans promoter (from the snb-1 gene).
Mutant animals at young adult stage showed decreased
locomotion in liquid, decreased pharyngeal pumping
Fig. 6 PLS3 overexpression and sym-2(RNAi) suppress endocytic defects caused by smn-1(RNAi) knockdown and summary. a Pie charts illustrating
the percentage of animals with the indicated accumulation of GFP in the body cavity. Soluble GFP is secreted from the muscle cells into the
body cavity. Coelomocyte-specific knockdown of smn-1 leads to GFP accumulation in the body cavity due to endocytic pathway defects. Either
coelomocyte-specific expression of PLS3 or coelomocyte-specific knockdown of sym-2 suppressed GFP accumulation, consistent with cell-
autonomous action of these proteins in coelomocytes. n > 40 animals pooled from multiple extrachromosomal array lines, combined from 3
independent trials. Scorers were blinded to the genotype of animals for each trial. Statistics calculated using chi-square. b Representative images
for “no body GFP,” “some body GFP,” and “strong body GFP.” c Based on results presented here and previous work, a summary of functional
genetic interactions is shown. c Normal levels of SMN protein facilitate appropriate transport and translation of “endocytic mRNAs,” which encode
proteins involved in endocytosis. As an actin-bundling protein, PLS3 may contribute to transport or localization of RNP granules (gray circles) that
contain “endocytic mRNAs,” as well as SMN, hnRNPF/H, and other proteins. d When SMN levels drop, the number, trafficking, or function of RNP
granules containing “endocytic mRNAs” is perturbed, resulting in fewer endocytic proteins and endocytic defects. e The deleterious
consequences of decreased SMN levels can be ameliorated by increasing PLS3 levels or by decreasing hnRNP F/H levels. The illustration of SMN
and hnRNP F/H in an RNP tethered by PLS3 is speculative, but increasing PLS3 or decreasing hnRNPF/H ortholog activity ameliorates both
functional defects and endocytic defects in the C. elegans model
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rates, and resistance to aldicarb, compared to their cor-
responding control animals (Additional file 1: Fig. S4,
p = 6 × 10−17, p = 1.1 × 10−8, p = 6.6 × 10−15, p = 3.7 ×
10−10, p = 4.7 × 10–4, p = 1.41 × 10−8) [30]. We introduced
the single-copy PLS3 transgene rtSi27 into both SOD1-
WT and SOD1-G85R to determine if these defects
would be suppressed.
Expression of PLS3 in SOD1-G85R animals proved to
be beneficial. Locomotion rates increased 61% compared
to SOD1-G85R animals lacking PLS3 (Additional file 1:
Fig. S4a, p = 3 × 10−6). Pharyngeal pumping defects were
similarly ameliorated; PLS3 expression increased pump-
ing rates by 35% in SOD1-G85R animals, restoring
pumping to normal levels (versus SOD1-G85R without
PLS3, Additional file 1: Fig. S4b, p = 4.1 × 10−8). Sensitiv-
ity to paralysis by aldicarb was also restored in SOD1-
G85R animals expressing additional PLS3, compared to
SOD1-G85R animals without PLS3 (Additional file 1:
Fig. S4c, p = 0.002). Overexpression of PLS3 does not in-
discriminately increase locomotion or pumping, nor
does it always change aldicarb sensitivity. SOD1-WT ani-
mals expressing PLS3 showed decreased locomotion
rates, compared to SOD1-WT animals without PLS3
(Additional file 1: Fig. S4a, p = 1.7 × 10−5). PLS3 had no
impact on pharyngeal pumping rates or aldicarb sensitiv-
ity in SOD1-WT animals (Additional file 1: Fig. S4b and
4c). Overexpression of SOD1-WT results in motor dys-
function, specifically in locomotion assays [57]. While
we observed this defect as well, it is unclear why overex-
pression of PLS3 is detrimental to SOD1-WT animals
when assessing locomotion but not for other behaviors.
However, due to the consistent beneficial effects in mu-
tant SOD1-G85R animals, we conclude that increased
plastin levels can suppress defects in a C. elegans model
of ALS.
To determine if PLS3 is beneficial outside of neurode-
generative disease models, we examined the impact of
overexpression on animals with decreased locomotion
due to synaptic defects. The unc-25 gene encodes the C.
elegans ortholog of mammalian GAD1 and is required
for ɣ-aminobutyric acid (GABA) synthesis [58]. The be-
havioral defects of these animals include a 65% decrease
in locomotion rates in liquid (Additional file 1: Fig. S5,
p = 5 × 10−25 unc-25(e156) versus wild type). PLS3 ex-
pression did not increase locomotion rates (p = 0.576
versus unc-25). The unc-13 and unc-57 genes encode C.
elegans orthologs of mammalian UNC13 proteins and
Endophilin A protein, which are critical for presynaptic
vesicular release and endocytosis, respectively. These
mutant animals move in an uncoordinated manner com-
pared to wild-type animals. PLS3 expression did not in-
crease locomotion of animals lacking unc-13 function,
but did increase locomotion in animals lacking unc-57
function (Additional file 1: Fig. S5, p = 0.02 unc-57
versus unc-57 with PLS3oe). Taken together, these re-
sults indicate that PLS3 overexpression is not generically
beneficial and ameliorating endocytic pathways may im-
prove function in C. elegans models of motor neuron
disease.
SYM-2 loss also improves locomotion in a C. elegans ALS
model
Considering that PLS3 overexpression suppressed de-
fects in a C. elegans disease model of ALS and the re-
lationship between PLS3 and SYM-2 described above,
it seemed plausible that sym-2 might also be a modi-
fier in an ALS model. We assessed the impact of
sym-2 on locomotion in the C. elegans SOD1 overex-
pression model. Using RNAi to knockdown sym-2
levels, SOD1-G85R animals had increased locomotion
rates with sym-2(RNAi) compared to empty vector
RNAi feeding (Additional file 1: Fig. S4d, versus con-
trol (RNAi), p = 3.7 × 10−8). These results suggest that,
reminiscent of PLS3, the beneficial impact of hnRNP
F/H loss and endocytic pathway changes may extend
to other motor neuron diseases.
Discussion
Elucidating how the pathology and symptoms of motor
neuron diseases can be suppressed should yield import-
ant insights into neurodegenerative mechanisms. Here,
we focused on understanding functional interactions be-
tween PLS3 and SMN, and on how their interaction pro-
vides insight into pathways pertinent to disease. We
confirm that increasing PLS3 suppresses locomotion de-
fects and endocytic pathway defects that are caused by
decreased SMN levels. In addition, we identify hnRNP
F/H as a component of protein complexes containing
SMN and PLS3. We demonstrate that decreasing levels
of the C. elegans hnRNP F/H ortholog SYM-2 also sup-
presses both locomotion and endocytic pathway defects
caused by diminished smn-1 function. Additionally, we
find that the beneficial impact of increased PLS3 or de-
creased SYM-2 expression is not limited to SMA; defects
in a C. elegans model of ALS are also suppressed. Fi-
nally, we show that interactions identified in C. elegans
are likely conserved, as PLS3, SMN, hnRNP F, and/or
hnRNP H1/2 are found together in mammalian neuronal
tissues and motor neuron processes. Combined, these
results suggest that SMN and PLS3 act to ameliorate
SMA defects via protein complexes that contain hnRNP
F and/or H1/2 that is pertinent to endocytic pathways.
Using mouse fibroblast cells and primary motor neu-
rons, we demonstrated that PLS3, SMN, hnRNP F, and
hnRNP H1/2 have an association and localize to the
same regions in vitro. Biochemical analysis confirmed
these findings in HEK293T cells and mouse brain ex-
tracts. Additionally, fractionation studies from mouse
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neuronal tissues and/or HEK293T cells suggested that
PLS3, SMN, and hnRNP F and/or H1/2 proteins can be
found in protein complexes. Given the biochemical in-
teractions identified in this study, the genetic interac-
tions observed between SMN-1, PLS3, and SYM-2 likely
also exist between the vertebrate orthologs SMN, PLS3,
and hnRNP F/H1/H2. Discovering how hnRNP F/H
family proteins interact with SMN and PLS3 will yield
insights into aspects of their function critical in disease.
hnRNPs are a diverse group of RNA binding proteins
originally named for their ability to bind hnRNAs (het-
erogeneous nuclear ribonucleic acids) [47]. hnRNP pro-
teins have diverse roles and are most commonly
involved in pre-mRNA processing, including mRNA ex-
port, localization, translation, and stability [42]. While
studies have identified that altering hnRNP F/H expres-
sion affects proliferation of cancer cells, virtually nothing
is known about their role or what altering hnRNP F/H
expression levels would do in a neurological context.
Here, we find that loss of SYM-2 suppresses endocytic
pathway defects in animals with decreased SMN-1 activ-
ity, identifying a new role for this specific hnRNP sub-
family. Understanding the function of hnRNPs beyond
their canonical role and identifying how they impact
endocytic pathways may lead to a better understanding
of endocytosis and SMA.
In C. elegans, mouse, and zebrafish models of SMA,
endocytic defects are seen at the NMJ [8–10]. In Hun-
tington’s and ALS models, clathrin-mediated endocytosis
is perturbed, potentially by protein aggregates that com-
pete with clathrin for chaperone proteins [59]. Further-
more, mutations in CHMP2B, part of a complex
involved in endosome-lysosome fusion, cause frontotem-
poral dementia [60]. Given these commonalities, we
speculate that perturbation of endocytic pathways may
be a critical step in neurodegenerative disease pathology.
Using genetic and functional studies, we showed in-
creased PLS3 expression or decreased SYM-2 expression
ameliorated endocytic pathway defects in a model of
SMA. This data reinforces that endocytic pathway de-
fects are critical in motor neuron disease and further
highlights the importance of understanding why these
hnRNPs are important in endocytosis.
Why does increasing PLS3 expression or decreasing
SYM-2 expression ameliorate behavioral defects in
models of SMA or ALS? Our results demonstrate that
these proteins colocalize with SMN, in motor neuron
processes. But how does this connect motor neuron dis-
ease to endocytic pathways? Previous work has shown
that increased PLS3 does not increase overall SMN pro-
tein levels [12, 15]. However, increased PLS3 may lead
to stabilization or transport of specific RNP complexes
that are disrupted when SMN levels decrease. Previous
work also demonstrated that a minimal amount of SMN
is required for PLS3 to ameliorate symptoms, consistent
with the more dramatic impact of PLS3 overexpression
on smn-1(cb131) partial loss of function versus smn-
1(ok355) complete loss of function animals. Previous
studies have also analyzed animals with decreased plastin
levels. In smn mutant zebrafish, PLS3 protein levels were
found to correspondingly decrease when SMN levels de-
creased. However, this correlation was not repeated
when profilin II levels were looked at, thus suggesting
the interaction with PLS3 is unique [38].
Using the results presented herein along with previ-
ously published work, we suggest a model in which the
balanced and coordinated action of SMN, PLS3, and
hnRNPF/H proteins promotes the optimal transport
and/or function of mRNAs and their encoded proteins,
and further that these mRNAs and proteins are essential
for normal endocytic function (Fig. 6). We suggest that
decreased levels of SMN negatively impact mRNAs re-
quired for endocytosis and that appropriate increased
expression of PLS3 or decreased expression of hnRNP
F/H levels can counteract these negative impacts. As
summarized in Fig. 6, decreased SMN protein levels may
lead to decreased function or transport in axons of RNP
granules containing hnRNP F/H. However, increasing
PLS3 leads to improved RNP granule transport or func-
tion, despite diminished SMN levels. Decreasing hnRNP
F/H may improve the translation and/or function of
endocytic proteins encoded by mRNAs within these
granules. In either case, increasing PLS3 or decreasing
hnRNP F/H improves endocytic function, which partially
ameliorates the deleterious consequences of diminished
SMN function.
Conclusions
Genetic studies are important in understanding disease
pathology and can yield novel and unexpected insights
into disease mechanisms. This is exemplified by the
identification of PLS3 and NCALD as modifiers of SMA
in patient families and the identification of hnRNP F/H
as a genetic modifier herein. Based on the level of con-
servation observed, it seems likely that decreasing
hnRNP F/H protein function would also be beneficial in
vertebrate SMA models, and potentially in ALS models
as well. The identification and functional interaction
identified between SMN, PLS3, and hnRNP F/H provide
insight into the mechanisms that lead to perturbations
in motor neuron disease.
Methods
C. elegans strains were maintained at 20 °C under stand-
ard conditions (Additional file 1: Table 1) [61]. All ani-
mals in experiments with smn-1(ok355) were first
generation progeny of heterozygous for the hT2 balancer
to preserve a uniform genetic background. RNAi studies
Walsh et al. BMC Biology          (2020) 18:127 Page 13 of 19
were undertaken in a sensitized background containing
the transgene, uIs72, that expresses the SID-1 double-
stranded RNA channel in neurons [62]. RNAi clones
were verified by sequencing and aligned for specificity to
the gene of interest. Only one RNAi clone was tested for
each gene of interest; however, in the case of smn-1 and
sym-2, loss of function alleles showed the same pheno-
type in behavioral testing. For behavioral assays with
transgenic animals, at least 3 integration lines were
tested to confirm results and rule out behavioral pheno-
types due to the integration site. All integrated trans-
genes were backcrossed to wild type at least three times
before final strain construction. The transgenic strains
rtSi27 and rtSi28 were generated by Mos-mediated
single-copy insertion [63]. The dpy-30 promoter was
cloned into pPD49.26 from the C. elegans expression
vector pS235, containing the dpy-30 promoter via SphI
and NheI sites. Human PLS3 CDS (ATG to TAA) was
amplified from pcDNA3.1_PLS3.V5-His6 TOPO vector
[9] using primers 5′-GAACGCTAGCATGGATGA
GATGGCTACCAC-3′ and 5′-CAGGGGAATGAAGA
GAGTGTAACCCGGGGTTC-3′ and cloned behind the
dpy-30 promoter creating dpy-30p::PLS3. Either the pro-
moter alone or the promoter with the PLS3 coding se-
quence was cloned into a modified pCFJ66 via SphI and
NheI or SphI and XmaI sites, respectively. The final con-
structs pHA#606 dpy-30p::unc-54UTR, unc-119(+) and
pHA#607 dpy-30p::PLS3::unc-54UTR, unc-119(+) were
injected at 50 ng/μl with the standard MosSCI cocktail
and injected into EG4322 (unc-119(ed3)III;cxTi10816 IV)
animals. Single-copy insertion events were identified
based on rescue of unc-119 in non-fluorescent animals
and confirmed by PCR genotyping. Transgenic strains
for neuronal and muscle-specific rescue were generated
by cloning the unc-119 or myo-3 promoters using SphI
and NheI sites into pHA#606 and pHA#607, in place of
the dpy-30 promoter. Both single-copy and multi-copy
transgenes were generated by injection of 50 ng/μl of
targeting plasmid into EG4322 (unc-119(ed3)III;
cxTi10816 IV) animals. Multi-copy insertion events were
identified based on the rescue of unc-119 in animals ex-
pressing fluorescent markers. Ceplst-1 overexpression
animals were created by amplifying plst-1 from the
yk1465f08 clone using primers 5′-GGTACCGGTT
TAATTACCCAAGTTTG-3′ and 5′-GAGCTCCAGA
AAAACCGAAAAAATCC-3′. The cDNA was placed
behind the dpy-30p in pPD49.26 using KpnI and SacI re-
striction sites. Either promoter alone or promoter with
plst-1 coding sequence was injected in smn-1(cb131);
ChR2 animals at 30 ng/μl along with the co-injection
marker pJM#67 elt-2p::GFP [64].
Coelomocyte plasmids were created by cloning either
PLS3 cDNA or sym-2 RNAi into the unc122p::smn-
1(RNAi) plasmid using AgeI and NotI. Primers for
amplification of sym-2 RNAi were as follows: 5′-gaac-
GAATTCTGAGAGGATTGCCTTATGATTGT-3′ and
5′-gaacACCGGTctcgatCTATTCCATCAAAATCG-3′.
Plasmids were injected into GS1912 at 40 ng/μl along-
side coel::RFP (Addgene #8938) also at 40 ng/μl. Trans-
genic lines tested are listed in Additional file 1: Table 1.
Selection of genes for analysis
To find proteins in a putative SMN/PLS3 complex, we
drew on published pull-down studies in Drosophila S2
cells [45]. We identified proteins that (i) independently
pulled down with Fimbrin or Smn with an HG score of
more than 61.5 (< 0.05 false discovery rate) consistent
with “strongly predicted interaction,” (ii) were not in the
top 10% of proteins pulled down in the entire database
(to avoid non-specific interactions), and (iii) had a C. ele-
gans loss of function allele available in 2011.
C. elegans assays
Retinal feeding was undertaken as previously described
[37] with modifications noted below. Transgenic animals
were cultivated in the dark at 20 °C on NGM plates with
OP50 bacteria with or without all-trans retinal (Sigma),
for approximately 18 h before experiments. Plates con-
taining all-trans retinal were prepared by spreading
100 μl of OP50 culture mixed with 1.6 μl of 100 mM all-
trans retinal stock (in ethanol) onto 2.5-cm plates con-
taining 5ml of NGM. After the animals were picked to
individual wells containing PBS and given 5min to accli-
mate to the environment, pre-blue light exposure videos
were taken using an AxioCam R3.0 camera at 12
frames/second, on a Zeiss SteREO Discovery V20 micro-
scope at × 137.5 magnification. Immediately following
the initial video, animals were illuminated with a mer-
cury bulb and a Zeiss bandpass filter set to 470 nm to
excite channelrhodopsin for 20 s. In order to maintain
consistent blue light dosage, light intensity was mea-
sured weekly using a spectrometer. To ensure all ani-
mals were equally exposed to blue light, a magnification
was chosen where the blue light field illuminated well
beyond the animals being studied. Post-exhaustion vid-
eos were then taken immediately following blue light
exposure.
Locomotion analysis was done with young adult ani-
mals that were individually picked into a single well of a
PDMS chip. Wells within the chip have a diameter of
1.6 mm and depth of 0.15 mm. Each well was preloaded
with 2 μl of PBS, and assays were performed at 22 °C.
After animals were placed in the wells, they were left un-
disturbed for 5 min to allow for acclimation to the envir-
onment. Locomotion rate was then assessed by taking
10-s videos at relevant time points with an AxioCam
R3.0 camera at 12 frames/second, on a Zeiss SteREO
Discovery V20 microscope at × 137.5 magnification.
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Movies were analyzed using the NABAS software, modi-
fied for image formats, and then translated to body
bends per minute [65]. A body bend is defined as a
muscle contraction resulting in a dorsal to ventral move-
ment across the midline of the animal. Average body
bends per minute (± SEM) were combined from at least
three independent trials (n ≥ 30 animals in total).
Pharyngeal pumping analysis was performed in the last
larval stage or in young adults as previously described
[39]. Pharyngeal grinder movement in any axis was
scored as a pumping event. Average pumping rates (±
SEM) were combined from at least three independent
trials (n ≥ 30 animals in total).
For locomotion studies, RNAi by feeding was done on
second generation (F2) animals reared on either control
(pL4440) or experimental, sym-2 [46], hrpf-1, or hrpf-2
dsRNA feeding vectors in HT115 bacteria and assayed.
The sym-2 RNAi clone contains genomic DNA inserted
into the pL4440 vector, corresponding to the last 3
exons and the 3′UTR of the gene, amplified by primers
5′-CTCGATCTATTCCATCAAAATCG and 5′-TGA-
GAGGATTGCCTTATGATTGT [66]. hrpf-1 and hrpf-2
RNAi clones were made by amplifying from genomic
DNA using the following primers, respectively, and
inserted into the pL4440 vector (5′-ATGGGAGGCC
ACTGAACAGG and 5′-GTGATCCATACGCCGCAG
AAT; 5′-CGCCCACTGATGTCCGTGG and 5′-
GCTGGAGATCATCGAAGTGG). RNAi clones were
verified by sequencing and aligned for specificity to the
gene of interest.
Aldicarb assays were conducted as described [67] with
noted modifications. Aldicarb (Sigma-Aldrich) was
added to NGM at a final concentration of 1 mM. Thirty
microliters of OP50 bacteria was seeded in the center of
the plates on the day of the assay. The plates were
allowed to dry without lids for at least 20 min. Approxi-
mately 15 young adult animals were transferred with a
platinum wire onto an aldicarb assay plate. The animals
were examined every hour and scored as paralyzed if
they did not pump or move after being prodded with a
platinum wire. The experimenter was blinded to the ge-
notypes/treatment. Average fraction of paralyzed ani-
mals (± SEM) was obtained by combining at least 3
independent trials (n ≥ 30 animals in total).
Coelomocyte endocytic assays were undertaken as de-
scribed previously [8]. Young adult animals were scored
as strong-intense GFP (body cavity filled), some-weak
GFP (little GFP in body cavity), or none-no GFP (no
GFP visible in the body cavity). Only animals expressing
the array in all 6 coelomocytes were scored (determined
by the presence of the coelomocyte specific RFP co-
injection marker) by an observer blinded to RNAi treat-
ment. Averages were determined over 3 independent tri-
als with an n > 40.
For the dispersal assay, 60 × 15mm NGM plates were
seeded with 200 μl of OP50 E. coli and evenly spread
over the entire surface. Three rings were drawn on the
bottom of the plate, starting 5 mm from center and
every 5 mm out towards the edge. Strains were main-
tained at 20 °C for the duration of the experiment. Ap-
proximately 24–32 young adult worms were manually
placed in the center of the plate and moved back to
20 °C. Every 60 min for 180 min, the strains were
counted and categorized based on which ring they were
in. Animals that moved outside the 3rd ring were
counted for total worm count. Data is represented as
fractional percent of animals located in each ring.
Preparation of primary murine embryonic fibroblasts
(MEFs), cell culture, and transfection
Primary murine fibroblasts were prepared from E13-14
animals as previously described [16]. Fibroblasts were
isolated from Smnko/wt;PLS3V5tg/tg embryos [9].
HEK293T cells and MEFs were grown in culture
medium (Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS), 1% peni-
cillin/streptomycin, and 0.1% amphotericin) at 37 °C and
5% CO2. Eighty percent confluent HEK293T cells were
transiently co-transfected with the respective vectors
using Lipofectamine 2000 (Invitrogen) and cultured in
OptiMEM. Fresh culture medium was added 6–12 h
post-transfection to the transfected cells. Cells were har-
vested 48 h post-transfection in PBS, and cell pellets
were stored at − 80 °C.
Immunofluorescence, immunoblotting, and antibodies for
MEFs and HEK293T cells
For immunofluorescent staining, MEFs were fixed with
4% paraformaldehyde in PBS for 15–20min. Fibroblasts
were permeabilized in 0.2% Triton X-100 in PBS for 5
min; blocked for 45 min in 5% FCS, 5% bovine serum al-
bumin (BSA) in PBST; incubated overnight at 4 °C with
the primary antibodies (1:50) in blocking solution;
washed with PBS; and incubated with the secondary
antibodies (1:200) and phalloidin (1/40) for 3–4 h. For
immunofluorescent staining, the following secondary
antibodies were used: AlexaFluor 488 (Do anti-Ms 1:300,
or Do anti-Rb, 1:300), AlexaFluor 350 (Do anti-Ms 1:
300, or Do anti-Rb, 1:300), and phalloidin AlexaFluor
568 (Invitrogen, A12380). Cells were imaged using a
fluorescence microscope (equipped with an ApoTome
(AxioImager M2, Zeiss)). For immunoblotting, the fol-
lowing primary antibodies with the listed concentrations
were used: mouse anti-V5 (Invitrogen, R960-25, 1:1000),
rabbit anti-hnRNP H2 (Novus Biologicals, NBP1-89816,
1:500), rabbit anti-hnRNP F (Novus Biologicals, NBP1-
57273, 1:500), rabbit anti-PLS3 ([12] 1:1000), anti-SMN
(BD Transduction Laboratories, 610647, 1:3000), and
Walsh et al. BMC Biology          (2020) 18:127 Page 15 of 19
anti-GFP (produced in hybridoma cell lines, 1:250). For
signal detection, the HRP-conjugated secondary anti-
bodies goat anti-mouse (Sigma, A4416, 1:5000) and goat
anti-rabbit (Cell Signalling, 7074, 1:5000) lgG were used
along with the SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific). For reprobing, the mem-
branes were stripped for 10 min with the Restore West-
ern Blot Stripping Buffer (Thermo Scientific).
Plasmids
Human hnRNP F (NM 001098208.1) and hnRNP H2
(NM 019597.4) cDNA was cloned into pcDNA3.1/CT-
GFP vector and human SMN1 (NM 000344.3) was
cloned into pcDNA3.1/V5-His vector via TOPO TA
cloning as described in the manufacturer’s protocol
(Invitrogen). Human PLS3 (NM 005032.6) cDNA was
cloned into pcDNA-Flag via MluI and NotI sites. The
pcDNA3.1/CT-GFP-TOPO vector (Invitrogen) was used
as a negative control for the co-immunoprecipitations.
Co-immunoprecipitation in HEK293T cells
For GFP-immunoprecipitation (IP), GFP MicroBeads, μ-
columns, and μMACS Separator (Miltenyi Biotec) were
used. μ-columns were permeabilized with 10% Triton X-
100 and washed twice with IP lysis buffer (100 mM
NaCl, 50 mM Tris, 5 mM EGTA, 1% CHAPS, pH 7.5,
containing protease inhibitor). Transfected HEK293T
cells were lysed for 20 min on ice in IP lysis buffer, soni-
cated for 10 min, and centrifuged for 20 min at 13,000
rpm at 4 °C. Next, 30 μl of GFP MicroBeads was added
to 500 μl cell lysate and incubated for 2 h at 4 °C. After
adding the cell lysates to the μ-columns, the μ-columns
were washed 5 times with IP lysis buffer, and proteins
were eluted from the μ-column using hot (95 °C) SDS
sample buffer. For RNase treatment, 100 μg/ml RNase A
(Invitrogen) was added to the IP lysis buffer. Eluates
were analyzed by SDS-PAGE and subsequent Western
blot.
Mouse motor neuron differentiation
Mouse wild-type hb9::GFP ES colonies were differenti-
ated into motor neurons during 6 days and dissociated
at day 7, using an embryoid body method as described
previously [68]. Briefly, after 2 days, EBs were treated
with retinoic acid (RAc; 100 nM, Sigma-Aldrich) and a
Hedgehog agonist (500 nM, Curis Inc.). On day 3, EBs
were treated with RAc (100 nM) and the Hedgehog
agonist (1 μM) and incubated for 96 h. On day 7, papain
(Worthington Biochemical) and DNase I were used to
dissociate EBs. Motor neurons were then dissociated,
plated into poly-ornithine coated greiner 96-well plates
(cat #655090) at a density of 20,000 cells per well, and
cultured in DMEM-F12 medium (Invitrogen) containing
2% FBS (Invitrogen), B-27 supplement (Invitrogen), 20
ng/ml GDNF and BDNF, CNTF (R&D Systems), insulin,
progesterone, BSA, selenite, and apotransferrin (Sigma-
Aldrich).
Immunocytochemistry of primary motor neurons
Day 13 motor neuron cultures were fixed using 8% PFA
for 15 min, followed by permeabilization and blocking
using 0.25% Triton X-100 and 10% normal goat serum
in PBS for 30 min. Detection of endogenous proteins
was performed using the following antibodies: mouse
anti-SMN antibody (BD Transduction Laboratories, di-
luted 1:200), rabbit anti-SMN antibody (Santa Cruz, di-
luted 1:200), mouse anti-PLS3 antibody (Santa Cruz,
diluted 1:500), rabbit anti-hnRNP H antibody (One
World Lab, diluted 1:1000), and rabbit anti-hnRNP F
antibody (Abcam, diluted 1:500). Secondary antibodies
for detection included AlexaFluor 546 (Gt anti-Rb, 1:
300, or Gt anti-Ms, 1:300) and AlexaFluor 647 (Gt anti-
Rb, 1:300).
Localization analysis
Images were taken on an Opera system (Perkin Elmer)
using a 40x water immersion lens with laser excitation
at 405, 488, 561 and 635 nM and used for analysis. Con-
focal stacks were taken using a Nipkow spinning disk at
1 μm slice intervals. Images were stacked together and
analyzed for localization of antibody staining using Per-
kin Elmer’s Columbus program (http://www.perkinel-
mer.com/pages/020/cellularimaging/products/columbus.
xhtml).
Co-immunoprecipitation (Co-IP) of mouse brain lysate
Whole adult mouse brains of Gad2-EGFP mice were
prepared by homogenization, using a Polytron
homogenizer in ~ 20ml of cold 1× RIPA buffer and then
incubated on ice for 30 min. Supernatant was collected
after a 20-min centrifuge step at 13,500 rpm in 4 °C and
stored at − 80 °C. Protein concentrations were deter-
mined using the BSA Protein Assay kit (Bradford).
Seven hundred fifty micrograms of lysate was incu-
bated with 2 μg of antibody for 1 h on a rotator at 4 °C.
During incubation, protein G beads were washed 5 times
in PBS and final bead suspension was added to lysate
mixture and incubated for 3 h on a rotator at 4 °C. The
bead mixture was centrifuged down and washed three
times, removing all supernatant. The beads were then
boiled in 2× SDS loading dye at 95 °C for 5 min to elute
the proteins. Eluted proteins were run on an SDS-
polyacrylamide gel for Western analysis.
Western analysis
Equal amounts of protein preparations were run and
separated on a 10% SDS-polyacrylamide gel electrophor-
esis and transferred to a PVDF membrane. Membranes
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were blocked with 5% milk in Tris-buffered saline con-
taining 0.1% Tween 20 (TBST) overnight at 4 °C. They
were probed with the antibody for 1 h at RT at the follow-
ing dilutions: mouse anti-SMN antibody (BD Transduc-
tion Laboratories, diluted 1:2500), mouse anti-PLS3
antibody (Santa Cruz, diluted 1:1000), rabbit anti-hnRNP-
H antibody (One World Lab, diluted 1:10,000), and rabbit
anti-hnRNP F antibody (Abcam, diluted 1:2500). After
washing with TBST, membranes were incubated with
HRP-conjugated secondary antibodies (anti-mouse or
anti-rabbit immunoglobulin-horseradish peroxidase, both
at 1:2500 dilution) at RT for 30min, and the blots were
developed using ECL and visualized on autoradiography
films. The presence of protein was determined based on
the size of the band compared to a ladder.
Size exclusion chromatography (SEC)
HEK293T cells were transfected with hnRNP F-GFP and
Flag/His-PLS3 vectors. The size exclusion chromatog-
raphy was performed on a Superose 6, 10/300 GL column
(GE Healthcare) connected to the FPLC system. The SEC
column was calibrated with gel filtration standard proteins
including thyroglobulin (669 kDa), ferritin (440 kDa), al-
dolase (158 kDa), ovalbumin (43 kDa), carbonic anhydrase
(29 kDa), and ribonuclease A (13.7 kDa). To solubilize
proteins including membrane fraction, cells were lysed in
the lysis buffer (1% NP40, 50mM Tris-HCl (pH 7.4), 150
mM NaCl, and 2mM MgCl2, containing protease inhibi-
tor cocktail). Lysis buffer without protease inhibitor was
degassed and used for column equilibration. The cell lys-
ate was sonicated and centrifuged at 13,000 rpm for 15
min. Two hundred fifty microliters of cell lysate was
injected into the column. Fractions of 0.5 ml were col-
lected and frozen at − 80 °C. Twenty-five microliters of
each fraction was analyzed by Western blotting.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
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Additional file 1: Figure S1. PLS3 overexpression suppressed
pharyngeal pumping defects in smn-1(ok355) animals. Homozygous null
smn-1(ok355) animals lacking smn-1 survive through early larval stages
due to maternal loading of SMN-1 proteins and mRNA by heterozygous
smn-1(ok355)/hT2 mothers. hT2 carries a functional copy of endogenous
smn-1, overexpression of human PLS3 slightly lowered pumping rates in
control smn-1(+) animals, but increased pumping rates in homozygous
smn-1(ok355) animals (compared to control smn-1(ok355)). To control for
genetic background all animals were derived from mothers heterozygous
for hT2. To control for transgene insertion position, control and smn-
1(ok355) animals carried rtSi28 [dpy-30p::empty]. PLS3 is overexpressed
from rtSi27 [dpy-30p::PLS3], a single copy insertion on chromosome II.
n≥30 animals per determination, combined from 3 independent trials
that the scorer was blinded to the genotype of animals. ANOVA
F(9.9,13.1) = 14.23, p<0.001; post-hoc Mann-Whitney U-test *p<0.05, S.E.
indicated. Figure S2. sym-2 knockdown using RNAi suppressed the smn-
1 locomotion defect. Exhaustion of cholinergic motor neurons using
ChR2 slowed locomotion; smn-1(cb131) animals with decreased SMN-1
function had aberrantly low locomotion rates post-exhaustion. RNAi
knockdown of hnRNP F/H ortholog sym-2 ameliorated this defect. empty
(RNAi) used as a control as the bacterial strain used for RNAi can alter
locomotion rates. n≥30 animals per determination, combined from 3 in-
dependent trials. Student’s t-test *p<0.05 S.E.M. indicated. Figure S3. As-
sociation of SMN and PLS3 with hnRNPF or hnRNPH1/2, is not
dependent on RNA. Pretreatment with RNase had no impact on co-
immunoprecipitation of PLS3 or SMN from HEK293T cells using GFP
tagged hnRNP F or hnRNP H1/2. SMN was tagged with V5; PLS3 was
tagged with Flag. Conditions and procedures as described in Fig. 4a. Fig-
ure S4.PLS3 and sym-2 suppress behavioral defects in specific C. elegans
models of neurodegenerative disease. (a) Neuronal overexpression of wild
type human SOD1 (SOD1-WT) had little impact on C. elegans locomotion,
but overexpression of SOD1 carrying the familial ALS patient allele G85R
(SOD1-G85R) dramatically decreased locomotion in young adult animals.
Introduction of ubiquitously expressed human PLS3 decreased locomo-
tion rates in SOD1-WT animals, but ameliorated defects in SOD1-G85R ani-
mals. ANOVA F(320.2,967.5) = 6.78, p<0.05 (b) SOD1-G85R animals had
decreased pharyngeal pumping rates in young adult animals. PLS3 ex-
pression restored normal pumping rates in SOD1-G85R animals. ANOVA
F(1305379,327194) = 235.38, p<0.001 (c) SOD1-G85R mutant animals were
resistant to the cholinesterase inhibitor aldicarb, based on slower time to
paralysis. Introduction of ubiquitously expressed human PLS3 restored
sensitivity to normal levels. (d) RNAi knockdown of sym-2 had no impact
on SOD1-WT animals, but increased locomotion rates in SOD1-G85R ani-
mals. Empty RNAi was used as a control for sym-2(RNAi) as bacterial strain
can alter locomotion and other behaviors. sym-2(RNAi) had no impact on
SOD1-G85R pumping rates (not shown). In this figure PLS3 was ubiqui-
tously expressed from rtSi27 [dpy-30p::PLS3], a single copy insertion on
chromosome II. In each assay an n≥30 animals per determination, com-
bined from 3 independent trials. In all trials scorers were blinded to the
genotype of the animals when collecting and scoring the data. Mann-
Whitney U-test (panels a,b,d,e and f) or Log Rank test (panels c and g)
**p<0.01 S.E.M. indicated. Figure S5. PLS3 does not generically suppress
locomotion. (a) C. elegans lacking glutamic acid decarboxylase encoded
by unc-25 had decreased locomotion in liquid due to defective GABA
synthesis (Jin et al., 1999). The ubiquitous expression of PLS3 did not sup-
press locomotion defects in unc-25;PLS3oe double mutant animals. PLS3
was overexpressed from rtSi27 [dpy-30p::PLS3], a single copy insertion on
chromosome II. The endogenous C. elegans plastin ortholog, plst-1, was
intact. Control single copy insertion rtSi28 did not express PLS3, but was
inserted at the same location on II, confirming that insertion into this
locus had no impact on unc-25 locomotion in this assay. n≥30 animals
per determination, combined from 3 independent trials. ANOVA
F(7.37,7.45) = 20.09, p<0.001 Mann-Whitney U-test: **p<0.01, S.E.M indi-
cated. b) PLS3 overexpression is unable to rescue the unc phenotype in
unc-13 animals when assessing dispersal on food. Animals are reported
as the percentage of animals that escaped the center ring after 1, 2 or 3
hours. Mean percent of animals escaped is calculated from three inde-
pendent trials of at least 24 animals per genotype, per trial. Each trial is
shown as a grey circle. Figure S6. Uncropped western blots. Panels a, d
and e correspond to Fig. 5 panels a, b and c, respectively. Panels b and c
correspond to supplementary figure 3. Table S1. Strains.
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